Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own5.60% Shs Outstand110.02M Perf Week-5.30%
Market Cap1.30B Forward P/E- EPS next Y-0.43 Insider Trans-11.33% Shs Float98.43M Perf Month-1.83%
Income-90.50M PEG- EPS next Q-0.31 Inst Own63.80% Short Float17.09% Perf Quarter10.07%
Sales104.60M P/S12.41 EPS this Y39.40% Inst Trans19.28% Short Ratio12.07 Perf Half Y23.82%
Book/sh-1.21 P/B- EPS next Y62.30% ROA-59.90% Target Price15.17 Perf Year45.68%
Cash/sh0.83 P/C14.16 EPS next 5Y5.60% ROE88.60% 52W Range5.53 - 13.84 Perf YTD4.42%
Dividend- P/FCF- EPS past 5Y-7.00% ROI-367.80% 52W High-14.74% Beta-
Dividend %- Quick Ratio1.00 Sales past 5Y117.70% Gross Margin- 52W Low113.38% ATR0.60
Employees306 Current Ratio1.00 Sales Q/Q13.80% Oper. Margin-69.60% RSI (14)44.90 Volatility3.85% 5.33%
OptionableYes Debt/Eq- EPS Q/Q-18.50% Profit Margin-86.40% Rel Volume1.22 Prev Close11.92
ShortableYes LT Debt/Eq- EarningsMay 07 Payout- Avg Volume1.39M Price11.80
Recom1.60 SMA20-1.90% SMA50-3.30% SMA20018.25% Volume1,696,141 Change-1.01%
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
May-15-15 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials
May-14-15 04:17PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
08:00AM  Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-13-15 07:45PM  Lightning Round: Don't know why this is so cheap at CNBC
May-08-15 10:30AM  Merrimack Pharmaceuticals' Q1 Loss Wider Than Expected - Analyst Blog
May-07-15 06:10PM  Merrimack reports 1Q loss
04:19PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:01PM  Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results PR Newswire
07:07AM  Q1 2015 Merrimack Pharmaceuticals Inc Earnings Release - Time Not Supplied
May-06-15 08:08AM  My Favorite Under $5 Biotech Could Soar 150% or More
May-05-15 03:10PM  Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog -5.78%
09:11AM  Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer at noodls
08:00AM  Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer PR Newswire
May-04-15 10:47AM  Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer at noodls
10:00AM  PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients PR Newswire
09:33AM  Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer at noodls
09:00AM  Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer Business Wire
Apr-28-15 04:22PM  Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference at noodls
04:15PM  Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference PR Newswire
Apr-27-15 09:00PM  PharmaEngine Announces Merrimack Completed MM-398 (PEP02) New Drug Application Submission to U.S. FDA Business Wire -8.49%
07:11AM  Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer at noodls
07:00AM  Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer PR Newswire
Apr-21-15 08:26AM  First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients at noodls
08:00AM  First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients PR Newswire
Apr-20-15 04:06PM  Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer at noodls
04:01PM  Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer PR Newswire
Apr-01-15 02:05PM  We're diversified and robust: Merrimack CEO
Mar-26-15 08:25AM  Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting at noodls
08:00AM  Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting PR Newswire
Mar-02-15 07:34PM  Lightning Round: I prefer this to Buffett's choice at CNBC +5.32%
Feb-27-15 03:03PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
02:38PM  Merrimack Pharmaceuticals Q4 Loss Narrower Than Expected - Analyst Blog
Feb-26-15 12:15PM  Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results at noodls
10:13AM  Merrimack reports 4Q loss
08:40AM  Merrimack Pharmaceuticals' (MACK) Loss Narrows in Q4 - Tale of the Tape
07:09AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
07:07AM  Q4 2014 Merrimack Pharmaceuticals Inc Earnings Release - Before Market Open
07:00AM  Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results GlobeNewswire
Feb-24-15 04:10PM  Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog Zacks
Feb-19-15 08:00AM  Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer GlobeNewswire
Feb-13-15 04:27PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-12-15 08:00AM  Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call GlobeNewswire
Jan-22-15 05:19PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
05:00PM  Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors GlobeNewswire
03:20PM  Merrimack Reveals Additional Data from Oncology Candidate - Analyst Blog Zacks
Jan-20-15 08:00AM  Merrimack Pharmaceuticals Presents Additional Analyses of Phase 3 MM-398 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium GlobeNewswire -5.98%
Jan-08-15 08:00AM  Merrimack Pharmaceuticals Announces Oral Presentation of Additional Analyses of MM-398 Phase 3 NAPOLI-1 Study at the American Society of Clinical Oncology (ASCO) 2015 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-07-15 08:00AM  Merrimack Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-17-14 08:16AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:00AM  Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors GlobeNewswire
Dec-12-14 08:00AM  Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium GlobeNewswire
Dec-04-14 08:00AM  Video Release -- Preclinical Research Differentiating the Activity of Merrimack's MM-398, Nanoliposomal Irinotecan (nal-IRI), Published in Cancer Research GlobeNewswire
Dec-01-14 04:01PM  Merrimack Pharmaceuticals to Present at Oppenheimer 25th Annual Healthcare Conference, Hold Analyst Day and Present Research on Multiple Molecules in December 2014 GlobeNewswire
Nov-25-14 11:15AM  Insider Trading Alert - FCS, GDOT And MACK Traded By Insiders at TheStreet
Nov-21-14 08:00AM  Merrimack Pharmaceuticals Presents on Multiple Programs at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics GlobeNewswire
Nov-20-14 04:20PM  Merrimack Pharmaceuticals' MM-398 Gets Fast Track Status Zacks
Nov-19-14 04:30PM  The S&P failed to extend its 4-day winning streak following headlines out of the Fed Yahoo Finance Blogs
12:34PM  Insider Trading Alert - MACK, GWRE And CCOI Traded By Insiders at TheStreet
08:00AM  Merrimack Pharmaceuticals Receives FDA Fast Track Designation for MM-398 in Post-Gemcitabine Metastatic Pancreatic Cancer GlobeNewswire
Nov-18-14 06:00AM  'Mad Money' Lightning Round: I'm Buy, Buy, Buying Biogen at TheStreet
Nov-17-14 09:09AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:30AM  Photo Release -- Merrimack Pharmaceuticals Announces the Addition of Vivian S. Lee, Dean of University of Utah School of Medicine, to Its Board of Directors GlobeNewswire
Nov-14-14 12:49PM  Insider Trading Alert - TASR, SAVE And MACK Traded By Insiders at TheStreet
Nov-13-14 08:00AM  Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 EORTC-NCI-AACR Symposium GlobeNewswire
08:00AM  Merrimack Pharmaceuticals to Present Advances on Targeted Cancer Molecules at the 2014 AACR-NCI-EORTC International Conference GlobeNewswire
Nov-10-14 06:57PM  Merrimack posts 3Q loss AP
04:17PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
04:01PM  Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results GlobeNewswire
07:07AM  Q3 2014 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close CCBN
Nov-07-14 03:35PM  Will Inovio (INO) Disappoint Expectations for Q3 Earnings? Zacks
03:30PM  Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? Zacks
Nov-06-14 03:02PM  Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? Zacks +5.03%
08:30AM  Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer GlobeNewswire
Nov-05-14 09:00AM  FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer GlobeNewswire -5.76%
05:49AM  Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? Zacks
Nov-03-14 08:00AM  Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call GlobeNewswire
02:23AM  Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% Zacks
Oct-31-14 03:11AM  Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% Zacks
03:07AM  Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% Zacks
Oct-30-14 03:19AM  ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% Zacks
Oct-27-14 08:08AM  Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? Zacks
02:15AM  Verastem (VSTM) Shows Strength: Stock Adds 7% in Session Zacks
02:12AM  BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% Zacks
Oct-24-14 04:25PM  Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case Zacks
06:47AM  Fate Therapeutics (FATE) Crumbles: Stock Tumbles by 10.6% Zacks
06:35AM  Merrimack Pharmaceuticals (MACK) Looks Strong: Stock Up 8.6% Zacks
Oct-22-14 06:43AM  Illumina (ILMN) Looks Strong: Stock Gains 9.2% Zacks
Oct-21-14 02:38AM  Vital Therapies (VTL) in Focus: Stock Adds 7.9% in Session Zacks
02:35AM  NewLink Genetics Corp. (NLNK) Jumps: Stock Rises 7.1% Zacks
Oct-20-14 04:24AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% Zacks
Oct-17-14 02:04AM  Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% Zacks
Oct-16-14 06:23AM  Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% Zacks +6.11%
06:20AM  Synageva BioPharma (GEVA) Shows Strength: Stock Up 7.4% Zacks
Oct-15-14 02:10AM  MiMedx Group (MDXG) Worth Watching: Stock Rises 9.7% Zacks
Oct-13-14 06:37AM  Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% Zacks
Oct-10-14 06:47AM  Why Merrimack (MACK) Could Be Positioned for a Surge? Zacks
Oct-07-14 04:01PM  Get Ready To Be Surprised This Earnings Season Zacks -5.19%
Oct-06-14 02:28PM  Top 5 Biotech Stocks Over The Past Year Benzinga
Sep-30-14 08:00AM  Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer GlobeNewswire
Sep-29-14 07:15AM  How Merrimack Pharmaceuticals (MACK) Stock Stands Out in a Strong Industry Zacks
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has completed Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398. The company's therapeutic oncology candidates also include MM-302 that is in Phase II clinical trial for the treatment of patients with ErbB2 (HER2)-positive, locally advanced or metastatic breast cancer; MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer, as well as ovarian, breast, and non-small cell lung cancers; and MM-111 that is in a Phase II clinical trial for the treatment of patients with advanced gastric, esophageal, and gastroesophageal junction cancers. In addition, its therapeutic oncology candidates consist of MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has collaboration and license agreements with Baxter International Inc., Baxter Healthcare Corporation, Baxter Healthcare SA, Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, and University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nielsen Ulrik B.DirectorMay 19Option Exercise2.4740,00098,800266,811May 19 05:04 PM
Nielsen Ulrik B.DirectorMay 19Sale13.0440,000521,600226,811May 19 05:04 PM
Sullivan William A.CFO and TreasurerMay 15Option Exercise2.1215,00031,80026,000May 19 05:02 PM
Stewart Edward J.Head of CommercialMay 15Option Exercise1.818,00014,48029,385May 19 05:03 PM
Stewart Edward J.Head of CommercialMay 15Sale12.338,00098,64021,385May 19 05:03 PM
Sullivan William A.CFO and TreasurerMay 15Sale12.3715,000185,55011,000May 19 05:02 PM
PORTER MICHAEL EDirectorMay 13Buy11.798,28497,668661,448May 15 07:53 AM
Nielsen Ulrik B.DirectorApr 20Option Exercise1.7740,00070,900266,811Apr 20 07:40 PM
Nielsen Ulrik B.DirectorApr 20Sale12.8840,000515,200226,811Apr 20 07:40 PM
Sullivan William A.CFO and TreasurerApr 15Option Exercise2.1215,00031,80026,000Apr 15 06:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolApr 15Option Exercise1.818,00014,48029,385Apr 15 06:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolApr 15Sale12.798,000102,32021,385Apr 15 06:07 PM
Sullivan William A.CFO and TreasurerApr 15Sale12.8715,000193,05011,000Apr 15 06:07 PM
Fehr Gordon J.DirectorApr 13Option Exercise1.7120,00034,200235,143Apr 15 06:07 PM
Fehr Gordon J.DirectorApr 13Sale13.0020,000260,000215,143Apr 15 06:07 PM
CROCKER GARY LDirectorApr 02Option Exercise2.1685,000183,3502,943,961Apr 10 09:41 AM
Mulroy Robert J.President and CEOMar 24Option Exercise1.94447,980868,4791,683,328Mar 25 05:26 PM
PORTER MICHAEL EDirectorMar 24Buy11.705,00058,500653,164Mar 26 08:41 AM
Mulroy Robert J.President and CEOMar 24Sale11.71103,9681,217,4651,509,316Mar 25 05:26 PM
Mulroy Robert J.President and CEOMar 23Option Exercise1.7110,40017,7841,349,716Mar 25 05:26 PM
Mulroy Robert J.President and CEOMar 23Sale11.6910,400121,5761,339,316Mar 25 05:26 PM
PORTER MICHAEL EDirectorMar 20Buy11.775,00058,850648,164Mar 24 09:14 AM
Nielsen Ulrik B.DirectorMar 19Option Exercise1.7140,00068,400266,811Mar 20 04:57 PM
Sullivan William A.CFO and TreasurerMar 19Option Exercise2.1215,00031,80026,000Mar 20 04:58 PM
Nielsen Ulrik B.DirectorMar 19Sale11.9740,000478,800226,811Mar 20 04:57 PM
Sullivan William A.CFO and TreasurerMar 19Sale11.9715,000179,55011,000Mar 20 04:58 PM
Schoeberl Birgit M.Head of DiscoveryMar 17Option Exercise1.7621,33737,62024,937Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 17Option Exercise1.812,0003,62023,385Mar 18 06:47 PM
PORTER MICHAEL EDirectorMar 17Buy11.771,19014,006644,354Mar 19 11:06 AM
Schoeberl Birgit M.Head of DiscoveryMar 17Sale12.0021,337256,0443,600Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 17Sale12.002,00024,00021,385Mar 18 06:47 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 16Option Exercise1.816,00010,86027,385Mar 18 06:47 PM
Schoeberl Birgit M.Head of DiscoveryMar 16Option Exercise1.7120,89735,82424,497Mar 18 08:53 PM
Schoeberl Birgit M.Head of DiscoveryMar 16Sale12.0020,897250,7643,600Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 16Sale11.936,00071,58021,385Mar 18 06:47 PM
Mulroy Robert J.President and CEOMar 05Option Exercise1.7122,38538,2781,361,701Mar 09 04:16 PM
Mulroy Robert J.President and CEOMar 05Sale12.5022,385279,8131,339,316Mar 09 04:16 PM
Nielsen Ulrik B.DirectorMar 04Option Exercise1.7120,00034,200246,811Mar 06 04:34 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 04Option Exercise1.816,00010,86027,385Mar 06 04:34 PM
Nielsen Ulrik B.DirectorMar 04Sale12.0120,000240,200226,811Mar 06 04:34 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 04Sale12.006,00072,00021,385Mar 06 04:34 PM
PORTER MICHAEL EDirectorMar 02Buy10.935,00054,650638,164Mar 04 07:37 AM
Nielsen Ulrik B.DirectorFeb 23Option Exercise1.7120,00034,200246,811Feb 24 04:20 PM
Nielsen Ulrik B.DirectorFeb 23Sale10.9120,000218,200226,811Feb 24 04:20 PM
Mulroy Robert J.President and CEOFeb 20Option Exercise1.71150,000256,5001,489,316Feb 20 04:14 PM
Mulroy Robert J.President and CEOFeb 20Sale10.94150,0001,641,0001,339,316Feb 20 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolFeb 17Option Exercise1.816,00010,86027,385Feb 19 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolFeb 17Sale10.316,00061,86021,385Feb 19 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolJan 15Option Exercise1.816,00010,86027,385Jan 16 05:46 PM
Stewart Edward J.SVP & Pres, Healthcare SolJan 15Sale11.196,00067,14021,385Jan 16 05:46 PM
Sullivan William A.CFO and TreasurerDec 24Option Exercise1.8115,00027,15026,000Dec 29 04:21 PM
Sullivan William A.CFO and TreasurerDec 24Sale10.7015,000160,50011,000Dec 29 04:21 PM
Lee Vivian SDirectorDec 23Buy10.2320,000204,60020,000Dec 23 01:34 PM
Sinskey Anthony JDirectorDec 18Option Exercise1.7120,00034,200442,543Dec 22 04:42 PM
Sinskey Anthony JDirectorDec 18Sale10.3120,000206,200422,543Dec 22 04:42 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 15Option Exercise1.766,00010,56027,385Dec 16 04:51 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 15Sale10.636,00063,78021,385Dec 16 04:51 PM
Mulroy Robert J.President and CEODec 08Option Exercise1.42118,247167,7021,339,316Dec 09 05:14 PM
Mulroy Robert J.President and CEODec 08Sale9.7325,000243,2501,270,232Dec 09 05:14 PM
Mulroy Robert J.President and CEODec 05Option Exercise1.25175,000218,7501,421,069Dec 09 05:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 05Option Exercise1.713,0005,13024,385Dec 09 05:19 PM
Stewart Edward J.SVP & Pres, Healthcare SolDec 05Sale10.003,00030,00021,385Dec 09 05:19 PM
Mulroy Robert J.President and CEODec 05Sale9.85175,0001,723,7501,246,069Dec 09 05:14 PM
PORTER MICHAEL EDirectorDec 02Buy8.718,00069,680633,164Dec 04 12:14 PM
PORTER MICHAEL EDirectorNov 21Buy9.005,67551,075625,164Nov 24 04:40 PM
PORTER MICHAEL EDirectorNov 20Buy8.766,23454,610619,489Nov 24 04:40 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 18Option Exercise1.711,0001,71022,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 18Sale9.001,0009,00021,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 17Option Exercise1.714,0006,84025,385Nov 18 05:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolNov 17Sale8.444,00033,76021,385Nov 18 05:07 PM
PORTER MICHAEL EDirectorNov 14Buy8.295,00041,450613,255Nov 18 05:08 PM
CROCKER GARY LDirectorNov 13Buy8.378,63072,2332,858,961Nov 14 10:11 AM
CROCKER GARY LDirectorNov 12Buy8.625,76049,6512,850,331Nov 14 10:11 AM
Stewart Edward J.SVP & Pres, Healthcare SolOct 23Option Exercise1.713,0005,13024,385Oct 24 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 23Sale9.053,00027,15021,385Oct 24 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Option Exercise1.714,0006,84025,385Oct 17 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolOct 15Sale8.004,00032,00021,385Oct 17 04:44 PM
Sullivan William A.CFO and TreasurerSep 30Option Exercise2.6940,878109,96251,878Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 30Sale8.9440,878365,44911,000Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Option Exercise2.1264,404136,53675,404Oct 01 05:04 PM
Sullivan William A.CFO and TreasurerSep 29Sale8.4064,404540,99411,000Oct 01 05:04 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Option Exercise1.7112,00020,52033,385Sep 26 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolSep 24Sale8.2212,00098,64021,385Sep 26 04:14 PM
Mulroy Robert J.President and CEOAug 29Option Exercise1.2519,83224,7901,246,069Sep 02 10:45 AM
Nielsen Ulrik B.SVP and CSOAug 26Option Exercise1.2550,00062,500226,811Aug 28 04:25 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Option Exercise1.2524,00030,00045,385Aug 28 04:23 PM
Stewart Edward J.SVP & Pres, Healthcare SolAug 26Sale6.8724,000164,88021,385Aug 28 04:23 PM
Sinskey Anthony JDirectorAug 25Option Exercise1.2525,00031,250422,543Aug 27 08:22 AM
Mulroy Robert J.President and CEOAug 21Option Exercise1.25280,168350,2101,226,237Aug 25 10:04 AM
PORTER MICHAEL EDirectorJun 23Buy6.8432,390221,548568,255Jun 24 09:16 AM
CROCKER GARY LDirectorJun 23Buy6.8436,000246,2402,844,571Jun 24 09:15 AM
Dresser James van B.DirectorJun 02Option Exercise1.2525,00031,250168,974Jun 03 01:26 PM